Based upon our present findings, it could be important to test whether 5-AzaC might also show clinical benefit in reducing levels of metastases, associated either with breast cancer or other tumors, perhaps preferentially for patients previously showing elevated levels of Src activity or with altered expression of factors acting downstream of activated Src. This evidence concerns the gene SRC and breast carcinoma.